“Pharma Bro” group files Ch11 following antitrust suit

“Pharma Bro” group files Ch11 following antitrust suit

A biopharmaceutical group whose founder Martin Shkreli infamously hiked the price of one of its best-selling drugs by 4,000% has entered Chapter 11, citing “reputation harm” and expensive litigation caused by Shkreli’s leadership.

Unlock unlimited access to all Global Restructuring Review content